Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Brigatinib produced responses in 23% of all tumors in patients with NF2-related tumors (schwannomas, meningiomas, and ependymomas), with hearing improvement in approximately one third...
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Brigatinib produced responses in 23% of all tumors in patients with NF2-related tumors (schwannomas, meningiomas, and ependymomas), with hearing improvement in approximately one third...
A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia
Weekly administration of an anti-CD38 antibody induced elevated platelet counts in 21 of 22 patients with refractory ITP. The main adverse events were infusion...
Homozygosity for R47H in TREM2 and the Risk of Alzheimer’s Disease
A meta-analysis of tests of association between variants in TREM2 and Alzheimer’s disease showed high risk among R47H homozygotes.
The New England Journal of Medicine:...
ViPOR’s Venom — Rationally Targeting DLBCL with Precision
Large B-cell lymphoma (LBCL) spans the gamut of aggressive lymphoid tumors with extensive biologic and clinical heterogeneity. Most patients with LBCL are cured with...
